The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed up by +0.38%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up by +0.10%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up by +0.56%. December...
The S&P 500 Index ($SPX ) (SPY ) today is up by +0.38%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down by -0.22%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up by +0.74%. December E-mini S&P...
/Alphabet%20Inc_%20and%20Google%20logos%20by%20IgorGolovinov%20via%20Shutterstock.jpg)
The S&P 500 Index ($SPX ) (SPY ) today is up by +0.41%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up by +0.02%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up by +0.60%. December E-mini S&P futures...
Trial met primary endpoint of hemoglobin response and key secondary endpoints of change from baseline in hemoglobin concentration and indirect bilirubin Trial showed trend favoring mitapivat but did...
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with...
Agios Pharmaceuticals: Q3 Earnings Snapshot
$12.9 million in third quarter PYRUKYND ® (mitapivat) net revenues PDUFA goal date for PYRUKYND U.S. sNDA in thalassemia set for December 7, 2025 CHMP adopted positive opinion for PYRUKYND in thalassemia;...
NEW YORK , Oct. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. ("Agios" or the "Company") (NASDAQ: AGIO). Such investors are...
CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with...
CAMBRIDGE, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with...